Cephalon receives EC authorization for Effentora
The European Commission (EC) has granted Cephalon marketing authorization for Effentora to treat breakthrough cancer pain. The drug has been selling in the U.S. under the trade name Fentora (fentanyl buccal tablets) since 2006 and is now under FDA screening for the treatment of other conditions associated with breakthrough pain, including neuropathic pain or lower back pain.
- Reata’s RTA 402 receives orphan drug status from FDA
- FDA grants priority review to RAD001
- Xoft receives FDA clearance for use of Axxent in endometrial cancer treatment
- Kansas cancer screening program runs out of funds
